Recursion Pharmaceuticals, Inc. RXRX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 7.2%— | 5%— | —— | —— | —— | |
| Operating margin | -881.3%+78.8pp | -867.9%-53.8pp | -1,656.2%-1,051pp | -1,005.8%-209pp | -960.1%-146pp | |
| Net margin | -842.9%+118pp | -863.4%-75.3pp | -1,637.8%-1,058pp | -1,004.9%-250pp | -961.3%-195pp | |
| EBITDA margin | -754.8%+124pp | -755.8%-3.7pp | -1,479.5%-923pp | -907.8%-175pp | -879.1%-125pp | |
| Free cash flow margin | -490.7%+174pp | -506.5%+127pp | -1,024.7%-515pp | -609.7%+79.6pp | -665.2%+49.0pp | |
| Returns | ||||||
| Return on equity | -57.2%+28.9pp | -59.5%+2.4pp | -91.1%-12.6pp | -86.3%-15.2pp | -86.1%-0.9pp | |
| Return on assets | -42.3%+19.4pp | -44.1%0.0pp | -67.3%-11.7pp | -62.5%-10.5pp | -61.7%-1.9pp | |
| Return on invested capital | -118.2%+48.6pp | -124.6%+16.3pp | -209.8%+54.2pp | -181.1%+61.5pp | -166.8%+349pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0×-0.1× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.5×+1.4× | 5.5×+1.7× | 4.6×+0.2× | 3.6×-2.5× | 4.1×-0.5× | |
| Quick ratio | 5.5×+1.4× | 5.5×+1.7× | 4.6×+0.2× | 3.6×-2.5× | 4.1×-0.5× | |
| Cash ratio | 5.1×+1.5× | 5.1×+1.9× | 4.3×+0.3× | 3.3×-2.4× | 3.6×-0.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | 0.1×-0.1× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | 0.1×-0.1× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $1.94-16.5% | $2.53-33.0% | $2.34+26.2% | $2.20-8.7% | $2.32+36.4% | |
| Valuation | ||||||
| Market capitalization | $1.62B-23.7% | $2.13B-19.4% | $2.13B+14.4% | $2.12B+16.8% | $2.13B-9.6% | |
| Enterprise value | $1.04B-39.8% | $1.47B-32.3% | $1.57B+1.4% | $1.7B+16.9% | $1.73B-17.3% | |
| Price / sales | 24.4×-11.1× | 28.5×-16.4× | 48.8×+20.2× | 32.8×-3.7× | 35.6×-15.3× | |
| Price / book | 1.6×-0.7× | 1.9×-0.7× | 2×-1.5× | 2.3×-0.8× | 2.3×-3.6× | |
| EV / sales | 15.7×-13.3× | 19.7×-17.2× | 35.8×+12.1× | 26.3×-3.0× | 29×-16.4× | |
| Free cash flow yield | -20.1%-1.4pp | -17.8%-3.7pp | -21%-3.2pp | -18.6%+0.3pp | -18.7%-4.7pp | |
| Earnings yield | -34.5%-7.5pp | -30.3%-12.7pp | -33.6%-13.3pp | -30.6%-10.0pp | -27%-12.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Recursion Pharmaceuticals, Inc.'s profit margins?
- Recursion Pharmaceuticals, Inc. (RXRX) runs a 7.2% gross margin and a -881.3% operating margin, with a -842.9% net margin.
- Where do Recursion Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Recursion Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.